|
Author
|
Design
|
Sample
|
Age (mean/median)
|
Male (%)
|
Hypertension (%)
|
HF (%)
|
CAD (%)
|
CLD (%)
|
Outcome
|
NOS
|
|---|
|
Baycan et al. [16]
|
Retrospective cohort
|
100
|
55.6
|
50
|
29
|
-
|
-
|
-
|
Mortality
|
8
|
|
Bursi et al. [17]
|
Retrospective cohort
|
49
|
65.7
|
63.3
|
49
|
6.1
|
22.4
|
12.2
|
Mortality
|
8
|
|
Croft et al. [6]
|
Retrospective cohort
|
58
|
54.1
|
58.6
|
68.9
|
17.2
|
22.4
|
13.8
|
Mortality
|
6
|
|
Janus et al. [7] (letter)
|
Retrospective cohort
|
31
|
64
|
-
|
-
|
-
|
-
|
-
|
Mortality
|
-
|
|
Kim et al. [15]
|
Prospective–retrospective cohort
|
40
|
60
|
50
|
37.5
|
0
|
0
|
0.03
|
Severity
|
8
|
|
Lassen et al. [4]
|
Prospective cohort
|
214
|
68.9
|
54.7
|
57
|
10.3
|
15.9
|
15
|
Mortality
|
8
|
|
Li et al. [8]
|
Cohort
|
120
|
61
|
48
|
40
|
-
|
9.2
|
5
|
Mortality
|
9
|
- CAD coronary artery disease, CLD chronic lung disease, HF heart failure, NOS Newcastle Ottawa Scale
